Clinical Trial Update: AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating AMG 162 for bone loss in men undergoing androgen-deprivation therapy for non-metastatic prostate cancer has completed with posted resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• AMG 162

Snippet

Sponsor: Amgen | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2014-06-03